Do analysts recommend MESO or ALKS?

Alkermes has a consensus target price of $54.56, suggesting a potential upside of 12.90%. Given Alkermes' stronger consensus rating and higher probable upside, analysts clearly believe Alkermes is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Alkermes 1 Sell rating(s) 4 Hold rating(s) 12 Buy rating(s) 1 Strong Buy rating(s) 2.72

Which has better earnings & valuation, MESO or ALKS?

Alkermes has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.20M 128.37 -$102.14M -$0.28 N/A Alkermes $1.48B 5.49 $241.66M $0.38 127.18

Is MESO or ALKS more profitable?

Alkermes has a net margin of 3.96% compared to Mesoblast's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Mesoblast's return on equity. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A Alkermes 3.96% 4.15% 2.19%

Does the media refer more to MESO or ALKS?

In the previous week, Mesoblast had 4 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Mesoblast and 4 mentions for Alkermes. Alkermes' average media sentiment score of 1.02 beat Mesoblast's score of 0.01 indicating that Alkermes is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral Alkermes 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer APGE or MESO?

Apogee Therapeutics currently has a consensus target price of $124.43, suggesting a potential downside of 7.66%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Apogee Therapeutics is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apogee Therapeutics 1 Sell rating(s) 15 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.20 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is APGE or MESO more profitable?

Mesoblast's return on equity of 0.00% beat Apogee Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Apogee Therapeutics N/A -29.88% -28.08% Mesoblast N/A N/A N/A

Does the media refer more to APGE or MESO?

In the previous week, Mesoblast had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 8 mentions for Mesoblast and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.39 beat Mesoblast's score of 0.01 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts recommend MESO or IBRX?

ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 82.28%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ImmunityBio 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has preferable earnings & valuation, MESO or IBRX?

Mesoblast has higher earnings, but lower revenue than ImmunityBio. Mesoblast is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.20M 128.37 -$102.14M -$0.28 N/A ImmunityBio $113.29M 72.88 -$351.40M -$0.97 N/A

Is MESO or IBRX more profitable?

Mesoblast has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. Company Net Margins Return on Equity Return on Assets Mesoblast N/A N/A N/A ImmunityBio -598.55% N/A -51.65%

Does the media favor MESO or IBRX?

In the previous week, Mesoblast had 6 more articles in the media than ImmunityBio. MarketBeat recorded 8 mentions for Mesoblast and 2 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.13 beat Mesoblast's score of 0.01 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral ImmunityBio 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RYTM or MESO?

Rhythm Pharmaceuticals currently has a consensus target price of $142.44, suggesting a potential upside of 29.49%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Rhythm Pharmaceuticals is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.78 Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor RYTM or MESO?

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Mesoblast. MarketBeat recorded 10 mentions for Rhythm Pharmaceuticals and 8 mentions for Mesoblast. Rhythm Pharmaceuticals' average media sentiment score of 0.56 beat Mesoblast's score of 0.01 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Mesoblast 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts rate MESO or TGTX?

TG Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 16.09%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TG Therapeutics is more favorable than Mesoblast. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mesoblast 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TG Therapeutics 1 Sell rating(s) 3 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.44

Which has better earnings and valuation, MESO or TGTX?

TG Therapeutics has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mesoblast $17.20M 128.37 -$102.14M -$0.28 N/A TG Therapeutics $616.29M 13.48 $447.18M $2.74 19.81

Does the media favor MESO or TGTX?

In the previous week, TG Therapeutics had 2 more articles in the media than Mesoblast. MarketBeat recorded 10 mentions for TG Therapeutics and 8 mentions for Mesoblast. TG Therapeutics' average media sentiment score of 1.08 beat Mesoblast's score of 0.01 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Mesoblast 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral TG Therapeutics 6 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Mesoblast (MESO) Competitors

$17.00 -0.43 (-2.47%)

As of 08/21/2026 04:00 PM Eastern

Compare

MESO vs. ALKS, APGE, IBRX, RYTM, and TGTX

Should you buy Mesoblast stock or one of its competitors? Mesoblast's main competitors and comparable companies include Alkermes (ALKS), Apogee Therapeutics (APGE), ImmunityBio (IBRX), Rhythm Pharmaceuticals (RYTM), and TG Therapeutics (TGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Mesoblast compare to Alkermes?

Mesoblast (NASDAQ:MESO) and Alkermes (NASDAQ:ALKS) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 95.2% of Alkermes shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 4.6% of Alkermes shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Alkermes has a consensus target price of $54.56, suggesting a potential upside of 12.90%. Given Alkermes' stronger consensus rating and higher probable upside, analysts clearly believe Alkermes is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72

Alkermes has a net margin of 3.96% compared to Mesoblast's net margin of 0.00%. Alkermes' return on equity of 4.15% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Alkermes	3.96%	4.15%	2.19%

In the previous week, Mesoblast had 4 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Mesoblast and 4 mentions for Alkermes. Alkermes' average media sentiment score of 1.02 beat Mesoblast's score of 0.01 indicating that Alkermes is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
Alkermes	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alkermes has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	128.37	-$102.14M	-$0.28	N/A
Alkermes	$1.48B	5.49	$241.66M	$0.38	127.18

Mesoblast has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market.

Summary

Alkermes beats Mesoblast on 13 of the 17 factors compared between the two stocks.

How does Mesoblast compare to Apogee Therapeutics?

Apogee Therapeutics (NASDAQ:APGE) and Mesoblast (NASDAQ:MESO) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations.

Apogee Therapeutics has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

Mesoblast's return on equity of 0.00% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Mesoblast	N/A	N/A	N/A

In the previous week, Mesoblast had 3 more articles in the media than Apogee Therapeutics. MarketBeat recorded 8 mentions for Mesoblast and 5 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.39 beat Mesoblast's score of 0.01 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Apogee Therapeutics currently has a consensus target price of $124.43, suggesting a potential downside of 7.66%. Given Apogee Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Apogee Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.20
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Mesoblast has higher revenue and earnings than Apogee Therapeutics. Mesoblast is trading at a lower price-to-earnings ratio than Apogee Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Mesoblast	$17.20M	128.37	-$102.14M	-$0.28	N/A

Summary

Apogee Therapeutics beats Mesoblast on 8 of the 15 factors compared between the two stocks.

How does Mesoblast compare to ImmunityBio?

Mesoblast (NASDAQ:MESO) and ImmunityBio (NASDAQ:IBRX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, analyst recommendations, valuation, profitability, risk, institutional ownership and media sentiment.

Mesoblast has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.03, suggesting that its share price is 97% less volatile than the broader market.

Mesoblast has higher earnings, but lower revenue than ImmunityBio. Mesoblast is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	128.37	-$102.14M	-$0.28	N/A
ImmunityBio	$113.29M	72.88	-$351.40M	-$0.97	N/A

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by company insiders. Comparatively, 66.1% of ImmunityBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Mesoblast had 6 more articles in the media than ImmunityBio. MarketBeat recorded 8 mentions for Mesoblast and 2 mentions for ImmunityBio. ImmunityBio's average media sentiment score of 1.13 beat Mesoblast's score of 0.01 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
ImmunityBio	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Mesoblast has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
ImmunityBio	-598.55%	N/A	-51.65%

ImmunityBio has a consensus target price of $14.20, suggesting a potential upside of 82.28%. Given ImmunityBio's stronger consensus rating and higher probable upside, analysts plainly believe ImmunityBio is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

ImmunityBio beats Mesoblast on 8 of the 15 factors compared between the two stocks.

How does Mesoblast compare to Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals (NASDAQ:RYTM) and Mesoblast (NASDAQ:MESO) are both mid-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and media sentiment.

Rhythm Pharmaceuticals currently has a consensus target price of $142.44, suggesting a potential upside of 29.49%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Rhythm Pharmaceuticals is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rhythm Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.78
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Rhythm Pharmaceuticals had 2 more articles in the media than Mesoblast. MarketBeat recorded 10 mentions for Rhythm Pharmaceuticals and 8 mentions for Mesoblast. Rhythm Pharmaceuticals' average media sentiment score of 0.56 beat Mesoblast's score of 0.01 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rhythm Pharmaceuticals	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mesoblast	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Mesoblast has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -85.59%. Mesoblast's return on equity of 0.00% beat Rhythm Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals	-85.59%	-159.87%	-44.00%
Mesoblast	N/A	N/A	N/A

Mesoblast has lower revenue, but higher earnings than Rhythm Pharmaceuticals. Mesoblast is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals	$189.76M	39.73	-$196.54M	-$3.11	N/A
Mesoblast	$17.20M	128.37	-$102.14M	-$0.28	N/A

1.4% of Mesoblast shares are owned by institutional investors. 5.9% of Rhythm Pharmaceuticals shares are owned by company insiders. Comparatively, 18.8% of Mesoblast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Rhythm Pharmaceuticals has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, Mesoblast has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

Summary

Mesoblast beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Mesoblast compare to TG Therapeutics?

Mesoblast (NASDAQ:MESO) and TG Therapeutics (NASDAQ:TGTX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

In the previous week, TG Therapeutics had 2 more articles in the media than Mesoblast. MarketBeat recorded 10 mentions for TG Therapeutics and 8 mentions for Mesoblast. TG Therapeutics' average media sentiment score of 1.08 beat Mesoblast's score of 0.01 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	2 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral
TG Therapeutics	6 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 55.22% compared to Mesoblast's net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Mesoblast's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
TG Therapeutics	55.22%	73.49%	34.14%

1.4% of Mesoblast shares are held by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are held by institutional investors. 18.8% of Mesoblast shares are held by insiders. Comparatively, 8.9% of TG Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Mesoblast has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.62, meaning that its share price is 62% more volatile than the broader market.

TG Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 16.09%. Given TG Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe TG Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TG Therapeutics	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44

TG Therapeutics has higher revenue and earnings than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$17.20M	128.37	-$102.14M	-$0.28	N/A
TG Therapeutics	$616.29M	13.48	$447.18M	$2.74	19.81

Summary

TG Therapeutics beats Mesoblast on 13 of the 16 factors compared between the two stocks.

Get Mesoblast News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MESO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MESO vs. The Competition

Export

Metric	Mesoblast	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.21B	$4.01B	$7.37B	$12.85B
Dividend Yield	N/A	3.64%	2.53%	11.08%
P/E Ratio	-60.71	11.62	272.60	24.24
Price / Sales	128.37	1,338.17	618.96	99.81
Price / Cash	N/A	105.14	78.62	53.99
Price / Book	3.64	16.80	13.05	6.20
Net Income	-$102.14M	-$12.50M	$3.47B	$348.59M
7 Day Performance	8.97%	3.29%	2.09%	0.08%
1 Month Performance	5.72%	8.23%	6.64%	3.88%
1 Year Performance	7.53%	55.05%	25.02%	16.98%

Mesoblast Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MESO Mesoblast	0.3642 of 5 stars	$17.00 -2.5%	N/A	+7.5%	$2.21B	$17.20M	N/A	80
ALKS Alkermes	3.1861 of 5 stars	$49.94 +0.2%	$54.56 +9.3%	+62.5%	$8.39B	$1.48B	131.69	2,050	Positive News
APGE Apogee Therapeutics	1.3679 of 5 stars	$134.58 0.0%	$124.43 -7.5%	+252.1%	$8.37B	N/A	N/A	91	Positive News
IBRX ImmunityBio	2.6518 of 5 stars	$7.67 -3.1%	$14.20 +85.1%	+237.2%	$8.14B	$113.29M	N/A	590	Positive News
RYTM Rhythm Pharmaceuticals	2.938 of 5 stars	$116.02 +0.5%	$142.44 +22.8%	+6.5%	$7.98B	$239.92M	N/A	140

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MESO) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mesoblast (MESO) Competitors

MESO vs. ALKS, APGE, IBRX, RYTM, and TGTX

How does Mesoblast compare to Alkermes?

Summary

How does Mesoblast compare to Apogee Therapeutics?

Summary

How does Mesoblast compare to ImmunityBio?

Summary

How does Mesoblast compare to Rhythm Pharmaceuticals?

Summary

How does Mesoblast compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mesoblast (MESO) Competitors

MESO vs. ALKS, APGE, IBRX, RYTM, and TGTX

How does Mesoblast compare to Alkermes?

Do insiders & institutionals hold more shares of MESO or ALKS?

Do analysts recommend MESO or ALKS?

Is MESO or ALKS more profitable?

Does the media refer more to MESO or ALKS?

Which has better earnings & valuation, MESO or ALKS?

Which has more risk and volatility, MESO or ALKS?

Summary

How does Mesoblast compare to Apogee Therapeutics?

Which has more volatility & risk, APGE or MESO?

Is APGE or MESO more profitable?

Does the media refer more to APGE or MESO?

Do analysts prefer APGE or MESO?

Do institutionals & insiders believe in APGE or MESO?

Which has stronger earnings and valuation, APGE or MESO?

Summary

How does Mesoblast compare to ImmunityBio?

Which has more risk and volatility, MESO or IBRX?

Which has preferable earnings & valuation, MESO or IBRX?

Do institutionals & insiders hold more shares of MESO or IBRX?

Does the media favor MESO or IBRX?

Is MESO or IBRX more profitable?

Do analysts recommend MESO or IBRX?

Summary

How does Mesoblast compare to Rhythm Pharmaceuticals?

Do analysts recommend RYTM or MESO?

Does the media favor RYTM or MESO?

Is RYTM or MESO more profitable?

Which has better valuation and earnings, RYTM or MESO?

Do insiders and institutionals hold more shares of RYTM or MESO?

Which has more volatility & risk, RYTM or MESO?

Summary

How does Mesoblast compare to TG Therapeutics?

Does the media favor MESO or TGTX?

Is MESO or TGTX more profitable?

Do insiders & institutionals have more ownership in MESO or TGTX?

Which has more risk & volatility, MESO or TGTX?

Do analysts rate MESO or TGTX?

Which has better earnings and valuation, MESO or TGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MESO vs. The Competition

Mesoblast Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools